Epsilon M&A Deal Report - ribosepharm
Transaction Multiples for the Valuation of Private Companies
Hikma Pharmaceuticals / ribosepharm
No EMAT :
17257
Announced Date :
22/01/2007
Type :
Acquisition of Majority Stake
Deal Value :
Yes
Acquirer :
Hikma Pharmaceuticals
Target :
ribosepharm
Country :
Germany
Sector of activity :
- Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Pharmaceuticals
Business Description :
Ribosepharm is a medium-sized company with national orientation and a focus on the development and distribution of oncology products and drugs for the treatment of different types of cancer >...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|||||||
| Current |
Rating :
**
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Pharmaceuticals » = 131
| Date | Acquirer | Target | Country | Multiples | See details |
| 27/05/2005 | Laboratoires Boiron | Unda | Belgium | *** | 17256 |
| 21/11/2006 | Crucell | SBL Vaccin | Sweden | ** | 17255 |
Source: Epsilon Research / EMAT
